Lixte Sale Purchase Of Stock vs Free Cash Flow Analysis

LIXT Stock

USD 1.96 0.01 0.51%

Lixte Biotechnology financial indicator trend analysis is infinitely more than just investigating Lixte Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lixte Biotechnology is a good investment. Please check the relationship between Lixte Biotechnology Sale Purchase Of Stock and its Free Cash Flow accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Sale Purchase Of Stock vs Free Cash Flow

Sale Purchase Of Stock vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lixte Biotechnology Sale Purchase Of Stock account and Free Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Lixte Biotechnology's Sale Purchase Of Stock and Free Cash Flow is 0.4. Overlapping area represents the amount of variation of Sale Purchase Of Stock that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Lixte Biotechnology Holdings, assuming nothing else is changed. The correlation between historical values of Lixte Biotechnology's Sale Purchase Of Stock and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Sale Purchase Of Stock of Lixte Biotechnology Holdings are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Sale Purchase Of Stock i.e., Lixte Biotechnology's Sale Purchase Of Stock and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.4

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Sale Purchase Of Stock

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from Lixte Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lixte Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

At this time, Lixte Biotechnology's Selling General Administrative is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 3.9 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 3.02 in 2024.

Lixte Biotechnology fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Other Current Assets	Common Stock Total Equity	Short Long Term Debt Total	Short Term Debt	Net Receivables	Inventory	Current Deferred Revenue	Net Tangible Assets	Preferred Stock Total Equity	Net Invested Capital
Total Assets		0.65	0.24	0.96	-0.97	-0.76	0.95	0.96	-0.28	0.76	0.24	1.0	-0.3	-0.32	0.46	0.81	-0.34	0.73	-0.11	0.91	-0.66	0.4	0.35	0.58	0.72	0.95
Other Current Liab	0.65		0.46	0.63	-0.63	-0.72	0.63	0.64	0.03	0.7	0.46	0.65	-0.19	-0.3	0.41	0.68	-0.5	0.54	-0.23	0.75	-0.47	0.42	0.72	0.37	0.55	0.66
Total Current Liabilities	0.24	0.46		0.21	-0.22	-0.45	0.22	0.23	0.18	0.43	1.0	0.24	0.13	-0.79	0.66	0.33	-0.21	0.26	-0.12	0.25	-0.01	0.71	0.48	0.04	0.2	0.16
Total Stockholder Equity	0.96	0.63	0.21		-1.0	-0.84	1.0	1.0	-0.31	0.86	0.21	0.96	-0.4	-0.3	0.42	0.8	-0.38	0.83	-0.35	0.88	-0.71	0.32	0.34	0.64	0.73	0.98
Net Debt	-0.97	-0.63	-0.22	-1.0		0.83	-1.0	-1.0	0.31	-0.85	-0.22	-0.97	0.38	0.3	-0.43	-0.79	0.42	-0.81	0.32	-0.89	0.72	-0.33	-0.34	-0.63	-0.75	-0.97
Retained Earnings	-0.76	-0.72	-0.45	-0.84	0.83		-0.84	-0.84	0.35	-0.99	-0.45	-0.75	0.38	0.48	-0.51	-0.73	0.28	-0.86	0.59	-0.72	0.71	-0.55	-0.69	-0.41	-0.79	-0.81
Cash	0.95	0.63	0.22	1.0	-1.0	-0.84		1.0	-0.31	0.86	0.22	0.95	-0.39	-0.3	0.43	0.78	-0.43	0.82	-0.36	0.88	-0.72	0.32	0.33	0.63	0.75	0.97
Cash And Short Term Investments	0.96	0.64	0.23	1.0	-1.0	-0.84	1.0		-0.28	0.86	0.23	0.96	-0.4	-0.31	0.44	0.79	-0.42	0.83	-0.36	0.88	-0.71	0.33	0.33	0.65	0.74	0.98
Common Stock Shares Outstanding	-0.28	0.03	0.18	-0.31	0.31	0.35	-0.31	-0.28		-0.33	0.18	-0.28	-0.01	0.01	0.04	-0.18	-0.2	-0.2	0.1	-0.1	0.37	-0.03	-0.31	0.04	-0.35	-0.25
Other Stockholder Equity	0.76	0.7	0.43	0.86	-0.85	-0.99	0.86	0.86	-0.33		0.43	0.76	-0.44	-0.46	0.46	0.74	-0.31	0.89	-0.64	0.74	-0.68	0.51	0.65	0.49	0.75	0.83
Total Liab	0.24	0.46	1.0	0.21	-0.22	-0.45	0.22	0.23	0.18	0.43		0.24	0.13	-0.79	0.66	0.33	-0.21	0.26	-0.12	0.25	-0.01	0.71	0.48	0.04	0.2	0.16
Total Current Assets	1.0	0.65	0.24	0.96	-0.97	-0.75	0.95	0.96	-0.28	0.76	0.24		-0.29	-0.32	0.46	0.81	-0.34	0.73	-0.1	0.91	-0.66	0.39	0.34	0.58	0.72	0.95
Common Stock	-0.3	-0.19	0.13	-0.4	0.38	0.38	-0.39	-0.4	-0.01	-0.44	0.13	-0.29		-0.35	0.16	-0.61	0.32	-0.77	0.51	-0.45	0.18	0.19	-0.21	-0.66	-0.11	-0.45
Property Plant And Equipment Net	-0.32	-0.3	-0.79	-0.3	0.3	0.48	-0.3	-0.31	0.01	-0.46	-0.79	-0.32	-0.35		-0.55	-0.17	-0.1	-0.2	0.12	-0.22	0.11	-0.87	-0.29	0.03	-0.33	-0.24
Accounts Payable	0.46	0.41	0.66	0.42	-0.43	-0.51	0.43	0.44	0.04	0.46	0.66	0.46	0.16	-0.55		0.4	-0.13	0.31	0.0	0.29	-0.54	0.44	0.29	-0.13	0.61	0.41
Non Current Assets Total	0.81	0.68	0.33	0.8	-0.79	-0.73	0.78	0.79	-0.18	0.74	0.33	0.81	-0.61	-0.17	0.4		-0.37	0.85	-0.16	0.83	-0.5	0.24	0.51	0.58	0.53	0.83
Other Current Assets	-0.34	-0.5	-0.21	-0.38	0.42	0.28	-0.43	-0.42	-0.2	-0.31	-0.21	-0.34	0.32	-0.1	-0.13	-0.37		-0.34	0.27	-0.49	0.27	0.03	-0.09	-0.44	-0.24	-0.35
Common Stock Total Equity	0.73	0.54	0.26	0.83	-0.81	-0.86	0.82	0.83	-0.2	0.89	0.26	0.73	-0.77	-0.2	0.31	0.85	-0.34		-0.6	0.77	-0.56	0.29	0.48	0.67	0.58	0.84
Short Long Term Debt Total	-0.11	-0.23	-0.12	-0.35	0.32	0.59	-0.36	-0.36	0.1	-0.64	-0.12	-0.1	0.51	0.12	0.0	-0.16	0.27	-0.6		-0.18	0.3	-0.14	-0.3	-0.38	-0.28	-0.3
Short Term Debt	0.91	0.75	0.25	0.88	-0.89	-0.72	0.88	0.88	-0.1	0.74	0.25	0.91	-0.45	-0.22	0.29	0.83	-0.49	0.77	-0.18		-0.53	0.33	0.47	0.66	0.58	0.9
Net Receivables	-0.66	-0.47	-0.01	-0.71	0.72	0.71	-0.72	-0.71	0.37	-0.68	-0.01	-0.66	0.18	0.11	-0.54	-0.5	0.27	-0.56	0.3	-0.53		-0.16	-0.3	-0.05	-0.96	-0.7
Inventory	0.4	0.42	0.71	0.32	-0.33	-0.55	0.32	0.33	-0.03	0.51	0.71	0.39	0.19	-0.87	0.44	0.24	0.03	0.29	-0.14	0.33	-0.16		0.46	0.05	0.43	0.28
Current Deferred Revenue	0.35	0.72	0.48	0.34	-0.34	-0.69	0.33	0.33	-0.31	0.65	0.48	0.34	-0.21	-0.29	0.29	0.51	-0.09	0.48	-0.3	0.47	-0.3	0.46		0.06	0.41	0.35
Net Tangible Assets	0.58	0.37	0.04	0.64	-0.63	-0.41	0.63	0.65	0.04	0.49	0.04	0.58	-0.66	0.03	-0.13	0.58	-0.44	0.67	-0.38	0.66	-0.05	0.05	0.06		0.06	0.66
Preferred Stock Total Equity	0.72	0.55	0.2	0.73	-0.75	-0.79	0.75	0.74	-0.35	0.75	0.2	0.72	-0.11	-0.33	0.61	0.53	-0.24	0.58	-0.28	0.58	-0.96	0.43	0.41	0.06		0.71
Net Invested Capital	0.95	0.66	0.16	0.98	-0.97	-0.81	0.97	0.98	-0.25	0.83	0.16	0.95	-0.45	-0.24	0.41	0.83	-0.35	0.84	-0.3	0.9	-0.7	0.28	0.35	0.66	0.71

Click cells to compare fundamentals

Lixte Biotechnology Account Relationship Matchups

Lixte Biotechnology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.7M	5.2M	5.1M	5.6M	4.3M	2.2M
Other Current Liab	237.9K	10.5K	302.9K	394.8K	313.9K	171.6K
Total Current Liabilities	237.9K	216.5K	302.9K	394.8K	313.9K	290.7K
Total Stockholder Equity	2.4M	5.0M	4.8M	5.2M	4.0M	4.2M
Net Debt	(2.6M)	(5.1M)	(4.8M)	(5.4M)	(4.2M)	(4.0M)
Retained Earnings	(27.1M)	(30.4M)	(37.1M)	(43.4M)	(48.5M)	(46.1M)
Cash	2.6M	5.1M	4.8M	5.4M	4.2M	4.4M
Cash And Short Term Investments	2.6M	5.1M	4.8M	5.4M	4.2M	4.4M
Common Stock Shares Outstanding	1.1M	1.1M	1.3M	158.2K	1.9M	1.8M
Liabilities And Stockholders Equity	2.7M	5.2M	5.1M	5.6M	4.3M	2.2M
Other Stockholder Equity	26.0M	31.9M	38.4M	45.1M	49.0M	51.4M
Total Liab	237.9K	216.5K	302.9K	394.8K	313.9K	290.7K
Total Current Assets	2.7M	5.2M	5.1M	5.6M	4.2M	2.2M
Accounts Payable	143.5K	190.3K	226.0K	229.8K	156.8K	169.4K
Other Current Assets	58.8K	159.2K	10.2K	10.4K	27.1K	25.8K
Short Term Debt	210.9K	237.9K	302.9K	394.8K	313.9K	193.4K
Current Deferred Revenue	94.3K	15.8K	77.0K	165.0K	157.1K	81.5K
Net Tangible Assets	625.8K	(1.1M)	1.5M	1.3M	1.5M	1.6M
Net Invested Capital	(1.1M)	1.5M	1.3M	1.7M	494.8K	317K
Net Working Capital	2.4M	5.0M	4.8M	5.2M	4.0M	4.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC